5 Speculative Biotech Analyst Stocks Under $10 With Massive Upside

We are coming into the fall and the third quarter, after a surprisingly solid push from the markets over the summer. Analysts may say it isn’t fundamentally sound but that does not detract from the gains. The high valuations, low volatility, no “sell in May and go away” and even weak economic data and earnings seem immaterial at this point. The bull market is now over seven years old. Still, the Dow, S&P 500 and Nasdaq still are flirting with all-time highs. Many investors are perplexed, and they also are looking for other ideas for how to make money ahead. 24/7 Wall St. reviews dozens of analyst research reports every day. This ends up being hundreds of analyst reports each week. Our goal is